TSX-002

Phase 2Small molecule

TTesoRx Pharma, LLC

TSX-002 is one of 34 small molecule programs targeting Hypogonadism. It is currently in Phase 2.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

HypogonadismActive, not recruiting

HypogonadismPhase 2

Active, not recruiting

Competition

Competitive Landscape

48 competitors in Hypogonadism

#DrugCompanyPhaseTrials

Victoza

Novo Nordisk

Approved

1 2

Estrace

Novo Nordisk

Approved

1 3

Andriol

AAuxilium

Approved

6 4

Jatenzo

GGrupo Espanol de Tumores Neuroendocrinos

Approved

5 5

Trelstar

OOncoVerity, Inc.

Approved

1 6

Arimidex

IIstituto Clinico Humanitas

Approved

1 7

Delatestryl

AAntares Pharma Inc.

Approved

1 8

Human Chorionic Gonadotropin

Merck & Co.

Approved

1 9

Depo-Testosterone

AAzurity Pharmaceuticals

Nizoral

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Clinical

Trials by Indication[1]

Hypogonadism2 trials

Oral Testosterone for the Treatment of Hypogonadism

Completed·TTesoRx Pharma, LLC·Phase 2·NCT01717768·130 enrolled

Oral Testosterone for the Treatment of Hypogonadism in Males

Completed·TTesoRx Pharma, LLC·Phase 2·NCT02222558·25 enrolled

Sources

References

[1]
ClinicalTrials.gov — 2 trial records for TSX-002. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — TSX-002 compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for TSX-002. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — TesoRx Pharma, LLC company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 2[1]
Company: TTesoRx Pharma, LLC

TSX-002

Status by Indication[3][1]

Competitive Landscape

Trials by Indication[1]

Hypogonadism2 trials

References

Drug Info

Quick Facts

Related News